Increased Doses Lead to Higher Drug Exposures of Levofloxacin for Treatment of Tuberculosis
Year: 2018
Type: article
Study design: Clinical Trial
Abstract: Patients with multidrug-resistant tuberculosis in Peru and South Africa were randomized to a weight-banded nominal dose of 11, 14, 17, or 20 mg/kg/day levofloxacin (minimum, 750 mg) in combination with other second-line agents. A total of 101 patients were included in noncompartmental pharmacokinetic analyses.
DOI: 10.1128/aac.00770-18
Authors: Charles A. Peloquin, Patrick P. J. Phillips, Carole D. Mitnick, Kathleen Eisenach, Ramonde F. Patientia, Leonid Lecca, Eduardo Gotuzzo, Neel R. Gandhi, Donna Butler, Andreas H. Diacon, Bruno Martel, Juan Santillan, Kathleen Robergeau Hunt, Dante Vargas, Florian von Groote-Bidlingmaier, Carlos Seas, Nancy Dianis, Antonio Moreno-Martinez, Pawandeep Kaur, C. Robert Horsburgh
Institutions: University of Florida, University of California, San Francisco, MRC Clinical Trials Unit at UCL, University College London, Harvard University, University of Arkansas for Medical Sciences, Stellenbosch University, Task Applied Science, Universidad Peruana Cayetano Heredia, Emory University, Westat (United States), Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública, Boston University
Language: English
Subfield: Pharmacology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Awards: Role of antigen-specific T cell responses in the control of TB, G158162940, Phase 2 Pharmacodynamic Study of High-dose Levofloxacin in MDR-TB Treatment, Biomarkers and Mechanisms of Paucibacillary and Latent Tuberculosis, Mentorship in Patient-Oriented Research in Tuberculosis, HIV and Global Health, Providence/Boston Center for AIDS Research (CFAR)
OpenAlex ID: W2883216123